-
Product Insights
Leucine Rich Repeat Kinase – Drugs In Development, 2023
Global Markets Direct’s Leucine Rich Repeat Kinase provides in depth analysis on Leucine Rich Repeat Kinase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leucine Rich Repeat...
-
Product Insights
Baculoviral IAP Repeat Containing Protein 5 – Drugs In Development, 2023
Global Markets Direct’s Baculoviral IAP Repeat Containing Protein 5 provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Baculoviral IAP Repeat Containing Protein 2 – Drugs In Development, 2023
Global Markets Direct’s Baculoviral IAP Repeat Containing Protein 2 provides in depth analysis on Baculoviral IAP Repeat Containing Protein 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Leucine Rich Repeat Containing Protein 32 – Drugs In Development, 2023
Global Markets Direct’s Leucine Rich Repeat Containing Protein 32 provides in depth analysis on Leucine Rich Repeat Containing Protein 32 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 – Drugs In Development, 2023
Global Markets Direct’s Leucine Rich Repeat Serine/Threonine Protein Kinase 2 provides in depth analysis on Leucine Rich Repeat Serine/Threonine Protein Kinase 2 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Leucine Rich Repeat Containing G Protein Coupled Receptor 5 – Drugs In Development, 2023
Global Markets Direct’s Leucine Rich Repeat Containing G Protein Coupled Receptor 5 provides in depth analysis on Leucine Rich Repeat Containing G Protein Coupled Receptor 5 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
NewLikelihood of Approval Analysis for Primary Immune Deficiency (PID)
Overview How likely is it that the drugs in Primary Immune Deficiency (PID) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Immune Deficiency (PID) Overview Primary immune deficiency (PID) is...
-
Product Insights
NewLikelihood of Approval Analysis for Cystic Fibrosis
Overview How likely is it that the drugs in Cystic Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cystic Fibrosis Overview Cystic fibrosis (CF) is an inherited disease that causes...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Parkinson's Disease Drug Details: FB-418 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FB-418 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FB-418 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FB-418 in Amyotrophic Lateral Sclerosis Drug Details: FB-418 is under development...